R-Pharm Group Becomes a New AIPM Member: Integration in the Best Interest of Russians

April 1, 2013, Moscow – The Association of International Pharmaceutical Manufacturers announces extension of the Association member list. On March 27, 2013 the General Meeting of AIPM members decided on the membership of R-Pharm Group. It is an important achievement for the Russian pharmaceutical market confirming the inconvertibility of partnership between Russian and international pharmaceutical companies and their further integration.

The processesof global integration have become typical of pharmaceutical industry. Pharmaceuticals can be manufactured in one country and distributed to the farthest corners of the globe or can be transnational by their nature with clinical trials, development and production carried out in different countries. Russia is currently actively involved in this process and R-Pharm Group is one of its leaders.

“АIPM is consistent in its policy towards the Russian companies that are ready to work in compliance with the international standards and welcomes the accession of R-Pharm Group with its far reaching aspirations towards the development, manufacturing and sales of innovative medicines including in cooperation with major international pharmaceutical manufacturers. We are convinced that R-Pharm accession to the Association will contribute to the common goal of making innovative high quality therapy affordable for Russian citizens,” said Vladimir G. Shipkov, Chief Executive Officer of the Association of International Pharmaceutical Manufacturers (AIPM).

“We are happy that our company has joined AIPM and look forward to efficient and long-term cooperation in compliance with the ethical principles and approaches of the Association. International cooperation is one of the priority directions for R-Pharm. Today we implement a number of projects on drug development and joint clinical trials with major international pharmaceutical companies and organizations. I expect that our contribution to the initiatives implemented by the Association of International Pharmaceutical Manufacturers, will promote the advancement of the public health system in Russia and provision of Russian patients with the most effective pharmaceuticals,” said Alexey E. Repik, Chairman of the R-Pharm Group Board of Directors.

Information: The Association of International Pharmaceutical Manufacturers (AIPM) comprises more than 50 international pharmaceutical companies that provide over 80% of the world’s pharmaceutical products and over 60% of medicines imported to the Russian Federation.

CJSC R-Pharm is one of the largest Russian pharmaceutical companies. The company has 36 branches and representative offices operating on the territory of the Russian Federation, the Group’s personnel amounts to over 2,500 professionals. The key areas of R-Pharm’s competence include research and development, manufacturing and market launch of wide range of pharmaceuticals used in hospital and specialty medical care. The principal activities of the company are manufacturing of finished dosage forms, active pharmaceutical ingredients of chemical nature and biotechnological substances, research and development of innovative medicines and technologies, launch of innovative highly effective pharmaceuticals on the Russian market, training and education for industry and health care specialists.

For more information please contact:

Alexei Shavenzov Communication Director at AIPM

tel.: +7 (495) 933 7040, e-mail: a.shavenzov@aipm.org   

Marina Rozhdestvina, AG-Loyalty

tel.: +7 (499) 788 91 57, mob.: +7 (985) 250 54 64, e-mail: mroz@ag-loyalty.com

Tatiana Gavrilenko, AG-Loyalty

tel.: +7 (499) 788 91 57, mob.: +7 (926) 796 29 39, e-mail: tgav@ag-loyalty.com

Evgenia Kasyanenko, Public Relations Manager R-Pharm Group

kasyanenko@rpharm.ru